CORE Biomedicine
Develops novel cancer therapeutics, backed by venture financing and an AMED grant to advance its oncology pipeline.
Overview
CORE Biomedicine is advancing novel cancer therapeutics for the oncology market. The company’s disclosed focus is on developing treatments intended to address cancer, though specific modalities, targets, or clinical-stage details were not provided. The company raised $21 million in Series A venture financing and also received an AMED grant award. That combination of venture capital and grant support provides funding context for its therapeutic development plans and distinguishes the round in the available disclosure.
Funding History
CORE Biomedicine Secures $21 Million Series A Venture Financing and Receives AMED Grant Award to Advance Novel Cancer Therapeutics
Frequently Asked Questions
- How much has CORE Biomedicine raised in total?
- CORE Biomedicine has raised a total of $21M across 1 funding round.
- What does CORE Biomedicine do?
- CORE Biomedicine is advancing novel cancer therapeutics for the oncology market. The company’s disclosed focus is on developing treatments intended to address cancer, though specific modalities, targets, or clinical-stage details were not provided. The company raised $21 million in Series A venture financing and also received an AMED grant award. That combination of venture capital and grant support provides funding context for its therapeutic development plans and distinguishes the round in the available disclosure.
- Where is CORE Biomedicine headquartered?
- CORE Biomedicine is headquartered in San Francisco, CA.
Related Insights
A comprehensive analysis of Isembard's funding history, investors, competitive position, and growth trajectory in the Deep Tech space.
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
395 AI funding deals worth $337B tracked in 2026. Complete guide to raising pre-seed, seed, Series A/B/C+ for AI startups. Valuations, metrics VCs demand, top investors (Sequoia, a16z, Lightspeed), and how AI funding differs from traditional tech. Includes real deal sizes, timelines, and founder strategies.